Trexquant Investment LP lessened its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 65.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,781 shares of the medical research company's stock after selling 83,021 shares during the period. Trexquant Investment LP's holdings in Agilent Technologies were worth $6,016,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of A. Cannon Advisors Inc. raised its stake in Agilent Technologies by 6.9% in the fourth quarter. Cannon Advisors Inc. now owns 3,026 shares of the medical research company's stock valued at $407,000 after purchasing an additional 196 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Agilent Technologies by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock valued at $938,291,000 after buying an additional 53,992 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Agilent Technologies by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock worth $1,250,276,000 after acquiring an additional 59,781 shares during the last quarter. O Shaughnessy Asset Management LLC grew its position in Agilent Technologies by 9.8% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 37,177 shares of the medical research company's stock worth $4,994,000 after acquiring an additional 3,327 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in Agilent Technologies by 1.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company's stock valued at $1,025,000 after acquiring an additional 87 shares during the last quarter.
Agilent Technologies Price Performance
Shares of NYSE:A traded down $8.52 during midday trading on Thursday, reaching $98.53. 1,324,614 shares of the company were exchanged, compared to its average volume of 1,831,127. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. The stock has a market cap of $28.09 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 2.79 and a beta of 1.19. The business's fifty day moving average is $125.62 and its two-hundred day moving average is $134.48. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $155.35.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The business had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.67 billion. As a group, analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.
Agilent Technologies Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's dividend payout ratio (DPR) is 22.76%.
Insider Activity at Agilent Technologies
In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel K. Podolsky sold 1,819 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the sale, the director now directly owns 35,737 shares of the company's stock, valued at $4,161,931.02. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,638 shares of company stock worth $731,229.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on A shares. TD Cowen upped their target price on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Thursday. Bank of America cut their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Barclays decreased their target price on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research report on Thursday. Robert W. Baird cut their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Finally, Citigroup raised their price objective on Agilent Technologies to $165.00 and gave the company a "buy" rating in a research note on Thursday, December 19th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and a consensus price target of $146.25.
Check Out Our Latest Research Report on A
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
